<DOC>
	<DOCNO>NCT00676533</DOCNO>
	<brief_summary>The primary objective clinical trial determine time improvement sign symptom ( eg , dysuria , frequency , urgency , gross hematuria , suprapubic pain , hesitancy , low back pain ) acute , uncomplicated , symptomatic , low UTIs woman treat Cipro XR 500 mg daily 3 day .</brief_summary>
	<brief_title>Cipro® XR Therapeutic Response Activity ( eXtRa ) - Assessing Symptom Relief Urinary Tract Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Nonpregnant , nonlactating woman age 18 65 year sign symptom acute , uncomplicated , symptomatic low UTI eligible enrolment . Dysuria least 1 clinical sign symptom low UTI ( frequency , urgency , suprapubic pain , gross hematuria ) present , symptom onset &lt; /= 72 hour study entry . In addition , 1 pretreatment cleancatch MSU culture positive 1 2 urinary pathogen ( &gt; /= 10.000 colonyforming unit { CFU } /mL ) . Women childbearing potential require use 2 reliable method contraception exposure study drug . Men Women pregnant , nursing , use 2 medically accept , effective method birth control Known suspect hypersensitivity ciprofloxacin quinolone class antimicrobial Subjects take urinary analgesic medication ( phenazopyridinecontaining product { eg , Pyridium } ) within 24 hour first dose study drug throughout study urinary tract pain Subjects take analgesic medication ( eg , nonsteroidal antiinflammatory drug [ NSAID ] , acetaminophencontaining product , etc ) urinary tract pain pain ( eg , headache , back pain , joint pain , dental pain , sore muscle , etc ) within 2 dose interval medication first dose study drug throughout study . More specifically , subject take medication pain could enter study time elapse since last dose medication equal least 2 dose interval medication . History gastrointestinal illness could interfere absorption orally administer antimicrobial Subjects require concomitant administration multivalent cationcontaining product magnesium/aluminum antacid , sucralfate , Videx ( didanosine ) chewable/buffered tablet pediatric powder , product contain calcium , iron , zinc , multivitamin preparation . These medication take less 6 hour 2 hour study drug administration . Subjects experience vaginitis Subjects temperature &gt; /= 38.3°C &gt; /= 101°F , flank pain , chill , manifestation suggestive upper UTI Subjects evidence factor predispose development UTIs , include calculus , stricture , primary renal disease ( eg , polycystic renal disease ) , neurogenic bladder Subjects currently take , might require , antibiotic Cipro XR study period Subjects receive systemic antibiotic therapy previous 48 hour , reason Subjects , opinion investigator , unsuitable enrollment unlikely complete course treatment available followup Subjects unable unwilling comply use electronic subject diary record UTI symptom impairment normal daily activity Subjects require concomitant administration theophylline Inability take oral medication reason Subjects &gt; /= 3 episode UTIs past 12 month Subjects onset symptom 72 hour prior study entry Subjects symptoms UTI within 4 week prior present episode Subjects previous history tendinopathy associate fluoroquinolones Subjects diagnose rapidly fatal underlying disease ( death expect within 6 month ) Subjects previously enrol clinical study Subjects know neutrophil count &lt; 1000/mm3 , CD4 &lt; 200/mm3 , condition associate significant depression host defense ; HIV test mandatory Subjects take investigational drug last 30 day Subjects could begin answer first visit baseline questionnaire 5:00 pm</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Cipro</keyword>
	<keyword>Urinary Tract Infection</keyword>
</DOC>